99mTc-3P-RGD2 molecular imaging targeting integrin αvβ3 in head and neck squamous cancer xenograft

Bing Yan; Fan Qiu; Ling Ren; Haojie Dai; Wei Fang; Haibo Zhu; Feng Wang

doi:10.1007/s10967-015-3928-5

^99mTc-3P-RGD2 molecular imaging targeting integrin α_vβ₃ in head and neck squamous cancer xenograft

J Radioanal Nucl Chem. 2015;304(3):1171-1177. doi: 10.1007/s10967-015-3928-5. Epub 2015 Feb 14.

Authors

Bing Yan¹, Fan Qiu², Ling Ren¹, Haojie Dai¹, Wei Fang³, Haibo Zhu⁴, Feng Wang²

Affiliations

¹ Department of Nuclear Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730 China.
² Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006 China.
³ Cardiovascular Institute & Fu Wai Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, 100037 China.
⁴ State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, 100050 China.

Abstract

^99mTc-3P-RGD2 and SPECT/CT were valuable tools for selecting patient likely benefit from integrin α_vβ₃ blocking therapy. To evaluate the feasibility of ^99mTc-3P-RGD2 imaging to detect head and neck squamous cell carcinoma, ^99mTc-3P-RGD2 was prepared and the relationship between its accumulation and integrin α_vβ₃ expression in nude mice bearing HEP-2 or CNE-1 carcinoma xenograft were analyzed. This study demonstrated that ^99mTc-3P-RGD2, with high affinity to integrin α_vβ₃, will provide basis for α_vβ₃ involved individual therapy.

Keywords: 99mTc-3P-RGD2; Angiogenesis; Head and neck squamous cell carcinoma; Integrin αvβ3; Molecular imaging.